VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
News|Articles|November 3, 2025
FDA updates in urology: October 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from October 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month’s notable regulatory decisions reflected the innovation coming down the pike, with a focus on priority reviews, fast track designations, and breakthrough device designations. From advancing next-generation therapeutics for bladder and prostate cancer to progressing minimally invasive technologies for stone disease, these updates underscore the ongoing progress across the spectrum of urologic care.
Related to this article
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement